SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Guided Therapeutics, Inc. (GTHPD)

GTHPD RSS Feed
Add GTHPD Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 11/18/2016 3:02:42 PM - Followers: 100 - Board type: Free - Posts Today: 0


 Guided Therapeutics, Inc.
 

About Us

Early Detection, Better Outcomes

Guided Therapeutics, Inc. has developed a platform technology for the early detection of disease that leads to cancer. Based on our patented biophotonic technology, the products use light to detect disease at the cellular level and provide painless and immediate results at the time of the examination.

Testing for cancer today usually involves a taking a tissue sample, like a biopsy, and sending it out to a specialist at a laboratory for results. Patients worry while waiting on test results and in many instances are given the wrong diagnosis – in most cases a false-positive result. A false positive diagnosis means the patient will undergo more testing only to discover later that they are healthy.

Our technology non-invasively scans the suspicious tissue with cool white light providing results, that studies have shown, can detect pre-cancer up to two years earlier than the tissue-sample method and with fewer false-positive results. This means less pain, no time waiting for results and fewer unnecessary treatments.

LuViva® Advanced Cervical Scan

Distributor Map

LuViva has distribution in 47 countries, with U.S. FDA review underway.

Our first non-invasive cancer detection product is the LuViva® Advanced Cervical Scan. LuViva is in use in Canada, Latin America, Europe, Asia and Africa and is under premarket application (PMA) review by the U.S. Food and Drug Administration.

LuViva is designed to determine the true likelihood of treatable cervical disease that may lead to cancer in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result. About 80% or more women with an abnormal result at this point in the testing process will eventually be diagnosed as having a false positive result – but after having an unnecessary colposcopy and biopsy. A one-minute scan with LuViva can rule out about 40% of the false-positive cases immediately without the need for colposcopy and biopsy. LuViva has also been shown in clinical trials to identify disease up to two years earlier than colposcopy and biopsy.

LuViva has also shown promise as a potential screening tool in the developing world to be used where the Pap test or HPV test are not widely available.  A clinical trial is underway to expand LuViva’s capabilities as a non-invasive cervical cancer screening product.

Cervical Cancer is a Big, Global Problem

After breast cancer, cervical cancer is the second most common cancer affecting women’s health. It is a leading cause of cancer deaths in the developing world for women of childbearing age.

Incidence of Cervical Cancer Worldwide:

  • 528,000 cases of invasive cancer (2012)
    266,000 deaths (2012)

In the U.S.:

  • 500,000 cases of precancer
    12,360 cases of cancer annually (2014)
    4,020 women will die from cervical cancer (2014)
    55-60 million Pap tests annually
    5.5-6 million follow-up referrals

Screening and diagnosis are effective but costly in developed regions of the world.  Common screening methods that lead to additional testing are positive for human papillomavirus (HPV) or an abnormal Pap test (cytology).

In developing regions, where screening methods are less commonly available, there is a different story.

“In sub-Saharan Africa, 34.8 new cases of cervical cancer are diagnosed per 100 000 women annually, and 22.5 per 100 000 women die from the disease. These figures compare with 6.6 and 2.5 per 100 000 women, respectively, in North America. The drastic differences can be explained by lack of access to effective screening and to services that facilitate early detection and treatment,” World Health Organization report.

Improving Cervical Cancer Detection with LuViva

Testing for cervical cancer today in the developed world involves taking a tissue sample – like a Pap test (cytology) for screening or a biopsy for diagnosis and sending the samples to a laboratory where they are read by a medical specialist. Results can take several days or weeks, delaying treatment and creating a time of uncertainty for the patient and her family.

In the developing world it’s a different story. Screening programs may be limited to a portion of the population in the larger cities with almost no screening is the rural areas.

LuViva can improve care in both situations.

In the Developed World:

Up to 80% or more of colposcopies and biopsies for for women who have abnormal Pap tests are found later to be normal or not necessary.  If HPV is used for screening those rates could go up.

Unmet Clinical Need for LuViva:  A non-invasive “triage” product to determine which patients that screen positive with Pap/HPV need a biopsy (true positives) and which don’t (normal or false positive).

In the Developing World:

Cervical cancer remains a leading cause of cancer death for women of childbearing age due to the lack of laboratory infrastructure.

Unmet Clinical Need for LuViva:  A non-invasive “screening” product that provides an immediate result in countries with little Pap/HPV screening.

Other Cancers

The platform technology that is LuViva can be applied to other forms or carcinoma. We’ve conducted human testing with the technology on patients at risk for esophageal cancer with promising results.  While a great deal more testing and development work needs to be done on that product, we believe that there is a need for our technology in the esophageal market.

Other cancers, in addition to cervical and esophageal, where the technology can be applied:

  • Head and Neck Cancer
    Anal Cancer
    Colorectal Cancer
    Skin Cancer

Our Business Model

Our business model is based on sales of a device, in this case the LuViva® Advanced Cervical Scan and a single-use, disposable patient interface called the Cervical Guide.  The continuing revenue from the Cervical Guides provides value for our shareholders. The Cervical Guide provides calibration of the LuViva before each test and assures the patient of a cross-contamination free examination.

Read more about our value propositions.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.
 

Website


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTHPD
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GTHP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 12/05/2016 05:23:17 PM
GTHP News: Quarterly Report (10-q) 12/05/2016 05:21:05 PM
GTHP News: Initial Statement of Beneficial Ownership (3) 11/18/2016 04:09:53 PM
GTHP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/17/2016 04:09:59 PM
GTHP News: Current Report Filing (8-k) 11/17/2016 04:07:24 PM
PostSubject
#4203   Pps still at $.0017 prior the reverse so yesterdaysnews74 11/18/16 03:02:41 PM
#4202   "Bit" of a slide at noon.... Catch_22 11/18/16 01:40:27 PM
#4201   I mean I guess it is progress in dawgma 11/17/16 05:51:13 PM
#4200   So is this a good sign? Catch_22 11/17/16 04:19:26 PM
#4199   I've never seen volume dry up this much dawgma 11/17/16 12:44:01 PM
#4198   Q3 earnings coming next. Let see, if they SolidRockCM 11/16/16 09:48:58 AM
#4197   I am ok waiting for a bit to dawgma 11/16/16 05:46:52 AM
#4196   I wouldn't go that far about Trumps future ahab333 11/15/16 11:38:51 AM
#4195   No telling how many more reverse are in yesterdaysnews74 11/15/16 10:58:04 AM
#4194   A third (3rd) R/S Yesterdaysnews74? I really ahab333 11/15/16 10:44:18 AM
#4193   Still have a ways to go with the yesterdaysnews74 11/15/16 10:34:37 AM
#4192   Down it goes! Soon after the reverse we'll yesterdaysnews74 11/15/16 10:26:04 AM
#4191   Well were almost there sub 1$ very soon yesterdaysnews74 11/15/16 10:05:58 AM
#4190   I think what happened is that the pps yesterdaysnews74 11/15/16 07:31:48 AM
#4189   I agree volume was very weak today...idk what dawgma 11/14/16 11:36:32 PM
#4188   Well was about to pull the trigger but yesterdaysnews74 11/14/16 12:38:46 PM
#4187   ONCI HAS BEGUN the PROCESS of REDUCING the VMAN06 11/14/16 10:31:13 AM
#4186   Yes I like companies that are real and dawgma 11/13/16 11:38:45 AM
#4185   You need to get your facts straight. The Lwe6638 11/11/16 01:23:28 PM
#4184   with grnh I take it your a valuevestor? show13iz 11/11/16 09:45:21 AM
#4183   I think it will very soon, next week dawgma 11/10/16 11:50:51 PM
#4182   Needs to get to 17$ for a break yesterdaysnews74 11/10/16 11:14:07 PM
#4181   https://www.insiderfinancial.com/guided-therapeutics-inc-otcbbgthp-is-closing-in dawgma 11/10/16 04:39:17 PM
#4180   Looking good Baby!!! watchful eye 33 11/10/16 01:41:12 PM
#4179   I'm here where did you see pending fda show13iz 11/10/16 11:36:43 AM
#4178   I guess everyone left this board since their dawgma 11/10/16 10:47:11 AM
#4177   No worries ahab, was just letting u know. 21money21 11/09/16 10:04:03 AM
#4176   I think the end of this month may dawgma 11/09/16 05:45:22 AM
#4175   You have my apologies 21Money, I had the ahab333 11/08/16 02:49:59 PM
#4174   Only AFTER the secondary....and accompanying dilution. Will be Lwe6638 11/08/16 02:06:30 PM
#4173   Good plan if it gets and stays over yesterdaysnews74 11/08/16 02:01:47 PM
#4172   One more trick in the bag. Get ready yesterdaysnews74 11/08/16 01:56:42 PM
#4171   One more trick in the bag. Get ready yesterdaysnews74 11/08/16 01:56:40 PM
#4170   It's traded over 20k shares.... 21money21 11/08/16 12:52:17 PM
#4169   WOW! R/S and then not even a ahab333 11/08/16 11:55:27 AM
#4168   GTHPD now has nothing left in its bag Zeppo 11/08/16 10:24:26 AM
#4167   Going to wait out the RS. Then will Dgoff 11/08/16 05:39:51 AM
#4166   See how long it stays above a buck, yesterdaysnews74 11/07/16 11:38:39 AM
#4165   Typical post reverse-split response....down! Lwe6638 11/07/16 11:09:33 AM
#4164   Good Morning RS! michaeldouglas 11/07/16 10:56:42 AM
#4163   No volume.... doncamel 11/07/16 09:55:58 AM
#4162   NO way.Bounce before RS is imminent. bigarow 11/07/16 08:10:02 AM
#4161   No reverse splits normally are bad for shareholders. dawgma 11/06/16 07:17:23 PM
#4160   I'll be keeping it on watch as they INeedDoeLikeABakery 11/05/16 11:55:13 PM
#4159   How high can the stock go is my dan__lam 11/05/16 02:50:36 PM
#4158   I look forward to running this company as dawgma 11/05/16 09:58:09 AM
#4157   FDA approval sooner then you think. runnersup 11/04/16 09:12:41 PM
#4156   agreed, But $GTHP is a share producing scam. fuego10 11/04/16 09:10:55 PM
#4155   Great I hope your right yesterday then I dawgma 11/04/16 09:01:30 PM
#4154   Knew that how trading was this week that yesterdaysnews74 11/04/16 06:39:42 PM
PostSubject